✦ LIBER ✦

[57] 3 YEARS OF ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY MINIMIZES THE RISK OF GENOTYPIC RESISTANCE TO ADV IN LAM RESISTANT PATIENTS

✍ Scribed by P. Lampertico; M. Vigano; E. Manenti; M. Tavarone; G. Lunghi; E. Del Ninno; M. Colombo

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

3 years of adefovir and lamivudine combi

✍ P. Lampertico; M. Viganò; E. Manenti; M. Iavarone; G. Lunghi; E. Del Ninno; M. C 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Genotypic analysis of lamivudine (LAM)-r

✍ S. Xiong; C. Westland; H. Yang; P. Lamy; H. Namini; A. Hung; C. Gibbs; M. Miller 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 131 KB

Low risk of adefovir resistance in lamiv

✍ Hiromi Yatsuji; Fumitaka Suzuki; Hitomi Sezaki; Norio Akuta; Yoshiyuki Suzuki; Y 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 238 KB

Four-year study of lamivudine and adefov

✍ J. Inoue; Y. Ueno; Y. Wakui; H. Niitsuma; K. Fukushima; Y. Yamagiwa; M. Shiina; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 480 KB

740 Emergence of dual-resistance HBV mut

✍ S.Y. Kwon; C.H. Lee; W.H. Choi; J.E. Yeon; K.S. Byun 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 239 KB

High risk of renal impairment during lon

✍ M. Viganò; P. Lampertico; M. Iavarone; G.E. Tontini; F. Facchetti; M. Colombo 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 72 KB